Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
parathyroid hormone replacement therapy |
| gptkbp:activeIngredient |
parathyroid hormone (PTH 1-34)
|
| gptkbp:approvalYear |
2023
|
| gptkbp:ATCCode |
H05AA10
|
| gptkbp:brand |
Palopegteriparatide
Yorvipath |
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Ascendis_Pharma
|
| gptkbp:effect |
decreases serum phosphate
increases serum calcium reduces need for oral calcium and vitamin D supplements |
| gptkbp:form |
injection
|
| gptkbp:halfLife |
approximately 60 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
TransCon PTH
|
| gptkbp:indication |
gptkb:hypoparathyroidism
|
| gptkbp:mechanismOfAction |
parathyroid hormone prodrug
|
| gptkbp:regulates |
approved in the United States
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:target |
parathyroid hormone receptor
|
| gptkbp:therapeuticArea |
endocrinology
|
| gptkbp:bfsParent |
gptkb:Ascendis_Pharma
|
| gptkbp:bfsLayer |
8
|